Publications
| Title | Abstract | Year Filter | PMID(sorted ascending) Filter |
|---|
| susceptibility of xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials. | the susceptibility of xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to a variety of newer antimicrobials was determined. sixty-three amikacin-resistant isolates were collected from 61 inpatients at a tertiary-care hospital between 1985 and 1988. the organisms included xanthomonas maltophilia (24 isolates), pseudomonas aeruginosa (16), pseudomonas species (3), serratia marcescens (10), flavobacterium meningosepticum (4), enterobacter species (3), acinetobacter calcoaceticu ... | 1991 | 1860303 |
| newly documented antimicrobial activity of quinolones. | the improved antimicrobial activity of newer fluoroquinolones and novel applications recently found for the drugs already marketed are reviewed. several new compounds are more active against gram-positive bacteria than the presently marketed fluoroquinolones. win 57273, the most potent compound in vitro on a weight basis, is 16 to 128 times more active than ciprofloxacin against various staphylococci, streptococci, enterococcus spp., corynebacterium spp., listeria monocytogenes and bacillus spp. ... | 1991 | 1864284 |
| isolation of a 30 kda immunoglobulin binding protein from pseudomonas maltophilia. | we have demonstrated that pseudomonas maltophilia (atcc no. 13637) possesses an exposed, immunologically accessible protein which binds to the fc region of several species of immunoglobulins. whole bacteria suspensions were incubated for 18 h with purified 125i-labelled antibodies with and without added non-labelled immunoglobulins. the suspensions were centrifuged for 30 min and the pellet containing bacteria was assessed for radioactivity. using this crude assay, the whole organism bound 125i- ... | 1991 | 1880425 |
| antibiotic susceptibility profile of xanthomonas maltophilia. in vitro activity of beta-lactam/beta-lactamase inhibitor combinations. | the susceptibility of 42 strains of xanthomonas (pseudomonas) maltophilia to 37 antibiotics (mainly beta-lactams, aminoglycosides, and fluorinated quinolones) was tested. xanthomonas maltophilia was resistant to most beta-lactams, with ceftazidime, moxalactam, and ici-194008 being the most active ones. aminoglycosides had a very modest activity, with quinolones showing only moderate activity against this species. trimethoprim/sufamethoxazole was effective against all strains tested. we also test ... | 1991 | 1889176 |
| in vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials. | a total of 3,144 clinical isolates from 3,011 consecutive patients were tested against lomefloxacin by the agar dilution method. they consisted of 1,380 isolates of enterobacteriaceae, 527 pseudomonads, 47 haemophilus influenzae, 53 acinetobacter, 42 brucella melitensis, 903 staphylococci and 192 strains of enterococci. in vitro activity of lomefloxacin was compared with ciprofloxacin, norfloxacin, beta-lactams and aminoglycosides. over 98% of enterobacteriaceae were susceptible to lomefloxacin ... | 1991 | 1889304 |
| combination effect of sce-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria. | the in vitro activity of cefepime and sce-2787, two new parenteral cephalosporins, and the combination effect with tobramycin and gentamicin against nosocomial gram-negative rods was studied using checkerboard agar dilution technique. cefepime showed excellent in-vitro activity against klebsiella pneumoniae, enterobacter cloacae, serratia marcescens and proteus vulgaris (mic90 0.03-0.125 mg/l) and good to moderate activity against acinetobacter anitratus, pseudomonas aeruginosa and pseudomonas c ... | 1991 | 1889877 |
| bacterial arthritis. | in this review of the 1990 septic arthritis literature, we revisit synovial fluid leukocytosis, examine the utility of synovial fluid glucose and protein measurements, and look at the levels of two cytokines, tumor necrosis factor and interleukin-1, in infected joint fluids. we see the many faces of gonococcal arthritis and the ravages of septic arthritis when the host has rheumatoid arthritis. should we recommend antibiotic prophylaxis for the rheumatoid patient with a prosthetic joint who is u ... | 1991 | 1911055 |
| treatment of pseudomonas infections in peritoneal dialysis patients. | pseudomonas species infections in the peritoneal dialysis population consist primarily of peritonitis or exit site infections. these organisms have traditionally proven difficult to eradicate, and the standard antibiotic regimen has carried the potential for nephrotoxicity. at our institution, all peritoneal dialysis patients with pseudomonas exit site infections or peritonitis were treated with an antibiotic combination of intraperitoneal ceftazidime and oral ciprofloxacin. treatment duration w ... | 1991 | 1912015 |
| purpura fulminans secondary to xanthomonas maltophilia sepsis in an adult with aplastic anemia. | purpura fulminans is a rare disease characterized by purpura ecchymosis, hypotension, and fever associated with disseminated intravascular coagulation. it often begins as a benign infectious process and subsequently progresses to a severe, catastrophic outcome. it is recognized to originate from congenital or acquired protein c deficiency. we present an unusual case of an adult with xanthomonas maltophilia sepsis that subsequently developed into purpura fulminans with involvement of the four ext ... | 1991 | 1918597 |
| in-vitro activity of meropenem, a new carbapenem, against imipenem-resistant pseudomonas aeruginosa and xanthomonas maltophilia. | the activity of meropenem, a new carbapenem, as well as imipenem, ceftazidime, aztreonam, tobramycin, amikacin and ciprofloxacin against 18 strains of xanthomonas maltophilia and 23 strains of pseudomonas aeruginosa resistant to imipenem was tested. all strains of x. maltophilia were resistant to both penems. ceftazidime, tobramycin and ciprofloxacin were the most active antimicrobial agents against this specie. 17% of imipenem-resistant strains of p. aeruginosa were sensitive to meropenem. cipr ... | 1991 | 1919651 |
| infections due to xanthomonas maltophilia in patients with hematologic malignancy. | 1991 | 1925296 | |
| in vitro comparison of gr69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates. | the activity of gr69153, a novel catechol-substituted cephalosporin, was compared with those of ceftazidime and ceftriaxone in a multicenter study against 5,203 fresh clinical isolates of gram-negative and gram-positive bacteria. gr69153 was generally very active at concentrations equivalent to or two- to fourfold lower than those of ceftazidime and ceftriaxone against gram-negative bacilli other than citrobacter freundii, enterobacter cloacae, and xanthomonas maltophilia. against pseudomonas ae ... | 1991 | 1929319 |
| in vitro antibacterial activity of me1207, a new oral cephalosporin. | me1207 is the prodrug of me1206. its in vitro antibacterial activity was compared with that of cefteram, cefpodoxime, cefixime, and cefaclor against various clinical isolates. me1206 was more active than the other cephems tested against staphylococci, streptococci, morganella morganii, pseudomonas cepacia, and flavobacterium meningosepticum and had the most potent activity against haemophilus influenzae and neiserria gonorrhoeae. the drug also showed a wide spectrum of activity against other gra ... | 1991 | 1929344 |
| imipenem/cilastatin as secondary therapy for bacterial infections. | imipenem/cilastatin (ipm/cs) was used to treat 39 documented infections in patients who had failed to respond to other antibiotic regimens. the overall response rating was 76.9%. respiratory infections responded less frequently (efficacy rating, 55.6%) to ipm/cs than abdominal infections, urinary tract infections, or sepsis. methicillin-resistant staphylococcus aureus, xanthomonas maltophilia, and acinetobacter calcoaceticus were less sensitive to ipm/cs therapy than the other bacterial strains ... | 1991 | 1933995 |
| susceptibility to beta-lactam antibiotics of mutant strains of xanthomonas maltophilia with high- and low-level constitutive expression of l1 and l2 beta-lactamases. | xanthomonas maltophilia produces two inducible beta-lactamases, l1 and l2, and resists the antimicrobial activity of beta-lactam antibiotics, including carbapenems. l1 is a zinc-metaloenzyme with carbapenemase activity; l2 is an unusual cephalosporinase. mutant strains with high- and low-level constitutive expression of these enzymes were derived from three reference strains of x. maltophilia. with a single exception, the mutant strains had altered expression of both enzymes, indicating that the ... | 1991 | 1941990 |
| beta-lactam antibiotic therapy in febrile granulocytopenic patients. a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. | to compare the efficacy, toxicity, and cost-effectiveness of double beta-lactam therapy with monotherapy. | 1991 | 1952471 |
| characterization of pseudomonas aeruginosa adherence to cultured hamster tracheal epithelial cells. | this study reports an in vitro system that allows the convenient study of both microenvironmental and bacterial factors affecting adherence of pseudomonas aeruginosa to tracheal epithelium. primary cultures of mixed ciliated and nonciliated epithelial cells isolated from hamster tracheas were grown on collagen-coated multiwell plates containing 10(5) epithelial cells/well at confluence. when 10(7) 14c-labeled p. aeruginosa (nonmucoid, strain y-4) suspensions were added to each well, 8.13 +/- 2.6 ... | 1991 | 1958384 |
| [antibiotic sensitivity of bacteria isolated from patients at 6 hospitals in osaka]. | we examined mics of 6 oral new quinolones and 4 oral cephems against bacteria isolated from patients at 6 hospitals in osaka during the period from january to june in 1990, and the following results were obtained. 1. all species excluding streptococcus pyogenes were more sensitive with less frequencies of resistance to new quinolones than to cephems. in new quinolones, tosufloxacin (tflx) was the most active against gram-positive cocci and ciprofloxacin (cpfx) and tflx had the highest activities ... | 1991 | 1960855 |
| application of multilocus enzyme electrophoresis to epidemiologic investigations of xanthomonas maltophilia. | to test the utility of a newly developed multilocus enzyme electrophoresis typing method for xanthomonas maltophilia. | 1991 | 2022862 |
| in vitro activity and beta-lactamase stability of gr69153, a new long-acting cephalosporin. | gr69153, a new parenteral cephalosporin, inhibited 90% of escherichia coli, klebsiella oxytoca, proteus mirabilis, citrobacter diversus, shigellae, and salmonellae at less than 0.25 micrograms/ml (mic90). it had activity comparable to those of ceftazidime, cefpirome, cefepime, and e-1040. against cephalosporinase-producing enterobacter cloacae, citrobacter freundii, and serratia marcescens, mics ranged from 0.12 to greater than 32 micrograms/ml, and cefpirome and cefepime were the most active ag ... | 1991 | 2024959 |
| isolation of a 48.5-kda membrane protein from pseudomonas maltophilia which exhibits immunologic cross-reaction to the beta-subunit of human chorionic gonadotropin. | in separate studies we have shown that pseudomonas maltophilia (american type culture collection 13637) possesses an immunoglobulin fc-binding protein. we have found that this protein prevents the application of immunoassays using monoclonal antibodies to study possible production of a cg-like material by this bacteria. employing an immunoglobulin saturation technique to block this protein as well as a zwitterion detergent membrane solubilization technique, we now report the isolation of a membr ... | 1991 | 2036979 |
| deoxyribonuclease from pseudomonas maltophilia. | 1991 | 2037173 | |
| in-vitro and in-vivo antimicrobial activities of a novel cephalosporin derivative, cp6162, possessing a dihydroxypyridone moiety at the c-3 side chain. | the antibacterial activity of a novel cephalosporin derivative, cp6162, possessing a dihydroxypyridone moiety at the c-3 side chain, was evaluated in vitro and in vivo, with ceftazidime, aztreonam and cefoperazone as the reference antibiotics. cp6162 showed weak or little activity against gram-positive bacteria, but potent activity against clinical isolates of the gram-negative species including strains of pseudomonas aeruginosa, ps. cepacia, acinetobacter sp., xanthomonas maltophilia, serratia ... | 1991 | 2050596 |
| pseudomonas maltophilia infections in neutropenic patients and the use of imipenem. | 1990 | 2084668 | |
| outer membrane protein d2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of pseudomonas aeruginosa. | the outer membrane of imipenem-resistant mutants of pseudomonas aeruginosa with decreased permeability to imipenem was shown by western (immuno-) blotting to contain protein d1 and to lack protein d2. protein d2 was purified and was shown to allow the permeation of imipenem at a rate higher than expected from its molecular weight. spontaneous imipenem-resistant mutants of p. aeruginosa pao1 appeared at a frequency of 10(-8) in the laboratory and did not synthesize protein d2. experiments perform ... | 1990 | 2109575 |
| antimicrobial resistance in the intensive care unit. | antimicrobial resistance remains a major clinical problem in the intensive care unit despite the introduction of potent new antibiotics and the application of infection control measures. impaired antibiotic permeability, antibiotic inactivation and alteration of antibiotic target sites, typically in concert, are mechanisms by which this resistance occurs. resistance traits may be chromosomally mediated, in which case they may be expressed constitutively or inducibly, or may be mediated by plasmi ... | 1990 | 2123990 |
| multicenter in vitro comparison of piperacillin and nine other antibacterials against 1,629 clinical isolates. | the antibacterial spectrum of activity of piperacillin was compared with that of other antibiotics against isolates of escherichia coli, enterobacter cloacae, haemophilus influenzae, klebsiella pneumoniae, pseudomonas aeruginosa, pseudomonas cepacia, pseudomonas maltophilia, serratia marcescens, enterococcus sp, bacteroides fragilis, bacteroides bivius, and clostridium difficile obtained from laboratories at hospitals in st. louis, in memphis, and in newark, new jersey. of the 1,629 isolates tes ... | 1990 | 2183941 |
| determination of peptidyl dipeptidase activity in 24 bacterial species. | of 24 bacterial species examined for lisinopril refractive peptidyl dipeptidase activity, only 8 contained activity. activity in pseudomonas maltophilia was more than fourfold higher than that of any other species. pseudomonas maltophilia may be unique among bacteria in possessing high peptidyl dipeptidase activity that is both edta inhibitable and lisinopril resistant. | 1990 | 2185870 |
| in vitro antibacterial activity and interactions with beta-lactamases and penicillin-binding proteins of the new monocarbam antibiotic u-78608. | u-78608, a new monocarbam antibiotic, was evaluated for in vitro activity against 312 clinical isolates of aerobic and anaerobic bacteria and subjected to several in vitro biochemical tests characterizing its interactions with beta-lactamases and penicillin-binding proteins (pbps). the antibacterial activity of the compound was compared directly with those of sq 83,360 (pirazmonam) and aztreonam. u-78608, sq 83,360, and aztreonam had generally poor activity against gram-positive aerobic bacteria ... | 1990 | 2193625 |
| evaluation of autoscan-w/a automated microbiology system for the identification of non-glucose-fermenting gram-negative bacilli. | we evaluated the ability of the autoscan-w/a (microscan division, baxter healthcare corporation, west sacramento, calif.), in conjunction with the dried colorimetric neg id type 2 panel (dcp) and new rapid fluorometric neg id panel (rfp), to identify non-glucose-fermenting gram-negative bacilli by challenging the system with 310 previously identified reference strains. of these 310 isolates, 286 organisms were in the dcp data base and 269 were in the rfp data base. use of the dcp panels resulted ... | 1990 | 2199522 |
| in vitro activity of ljc10,627, a new carbapenem antibiotic with high stability to dehydropeptidase i. | the in vitro activity of ljc10,627, a new carbapenem, was compared with those of imipenem and ceftazidime. ljc10,627 had broad-spectrum activity against gram-positive and gram-negative clinical isolates. the mics of this compound for 90% of members of the family enterobacteriaceae tested (mic90s), including strains resistant to ceftazidime, ranged from 0.1 to 25 micrograms/ml. ljc10,627 inhibited pseudomonas aeruginosa at an mic90 of 3.13 micrograms/ml; it thus was twofold more active than imipe ... | 1990 | 2203313 |
| in vitro activity of pd127,391, a new quinolone against bacterial isolates from cancer patients. | the in vitro activity of pd127,391, a new 4-quinolone, was compared to that of ciprofloxacin against common clinical bacterial isolates from patients with cancer. pd127,391 was found to have a broad antimicrobial spectrum with excellent activity against gram-positive isolates (including multidrug-resistant organism such as corynebacterium jeikeium, enterococcus faecalis, enterococcus faecium, methicillin-resistant staphylococcus aureus and coagulase-negative staphylococcus spp.). it was also ext ... | 1990 | 2209169 |
| in vitro antibacterial activity and beta-lactamase stability of the new carbapenem ljc10,627. | in in vitro susceptibility tests the new carbapenem ljc10,627 showed potent antibacterial activity against gram-positive and gram-negative bacteria, except that most methicillin-resistant staphylococcus aureus strains tested were found to be resistant to ljc10,627. ljc10,627 showed high activity against pseudomonas aeruginosa and was active against enterobacter cloacae and citrobacter freundii strains which were resistant to ceftazidime and cefpirome. the ki values of ljc10,627 for penicillinase ... | 1990 | 2209630 |
| in vitro susceptibility of xanthomonas (pseudomonas) maltophilia to newer antimicrobial agents. | the susceptibilities of 45 clinical and 3 environmental isolates of xanthomonas maltophilia to 14 antimicrobial agents was determined by broth microdilution. the newer quinolones pd117596, pd117558, pd127391, a-56620, amifloxacin, and fleroxacin were the most active agents tested, with 70 to 99% of isolates being susceptible to these agents. all isolates were resistant to trospectomycin. the new aminoglycosides sch24120 and sch22591 were active against 12 and 1% of isolates, respectively. | 1990 | 2221872 |
| nosocomial infections due to xanthomonas maltophilia (pseudomonas maltophilia) in patients with cancer. | from december 1985 to may 1986, xanthomonas maltophilia (formerly known as pseudomonas maltophilia) was isolated at an increased rate at our institution; 52 isolates of x. maltophilia were obtained in cultures of clinical specimens from 38 patients during that time. the records of 35 of these patients form the basis of this study. twelve (71%) of the 17 infected and nine (50%) of the 18 colonized patients had received or were receiving antimicrobial therapy. eleven of 17 patients (three of seven ... | 1990 | 2267495 |
| numerical analysis of 295 phenotypic features of 266 xanthomonas strains and related strains and an improved taxonomy of the genus. | an extensive phenotypic description and an improved classification and nomenclature of the genus xanthomonas are presented. a total of 266 strains obtained from different geographical areas, including representative strains of all species of the genus xanthomonas and most pathovars of xanthomonas campestris, as well as strains which might be genetically related to the genus xanthomonas, were examined for 295 morphological, biochemical, and physiological features. similarities among the strains w ... | 1990 | 2275852 |
| in vitro activity of hre 664, a penem antibiotic. | hre 664, a new penem antibiotic, inhibited 90% of escherichia coli, klebsiella, citrobacter diversus, proteus mirabilis, proteus vulgaris, salmonella, shigella, providencia, aeromonas, and morganella at less than or equal to 2 micrograms/ml but was considerably less active than cefotaxime, ceftazidime, and imipenem. it did not inhibit pseudomonas aeruginosa (mic greater than 128 micrograms/ml). hre 664 inhibited enterobacter spp., citrobacter freundii, and serratia marcescens at 1-8 micrograms/m ... | 1990 | 2279381 |
| comparative in vitro activities of newer quinolones against pseudomonas species and xanthomonas maltophilia isolated from patients with cancer. | the in vitro susceptibilities of three pseudomonas species (pseudomonas aeruginosa, pseudomonas putida, and pseudomonas fluorescens) and xanthomonas maltophilia to quinolone antimicrobial agents were determined. several newer agents, particularly pd117558, pd117596, pd127391, sparfloxacin (at-4140), a-56620, and temafloxacin, were active against pseudomonas species. x. maltophilia isolates were generally less susceptible than were pseudomonas isolates but were inhibited by some of the newer quin ... | 1990 | 2285297 |
| [susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium]. | in vitro antibacterial activities of imipenem/cilastatin sodium (imipenem) and other beta-lactams against clinically isolated 353 bacterial strains were investigated. the results obtained in this study are summarized as follows: 1. imipenem (ipm) showed potent antibacterial activities against gram-positive cocci such as staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, streptococcus agalactiae. 2. ipm had inferior or equivalent antibacterial activities to beta-lactams aga ... | 1990 | 2287059 |
| heterogeneity of beta-lactamase production in pseudomonas maltophilia, a nosocomial pathogen. | twenty pseudomonas maltophilia isolates were examined for susceptibility to beta-lactam antibiotics, including carbapenems, and for beta-lactamase production. all the isolates were resistant to imipenem (mics 64-512 mg/l) and to a lesser extent, to meropenem (mics 16-256 mg/l). none of the isolates produced significant amounts of beta-lactamase without induction. among the beta-lactams studied imipenem proved to be the most potent inducer; meropenem was a weaker inducer. interestingly, 6-amino-p ... | 1990 | 2311440 |
| nosocomial infection caused by xanthomonas maltophilia: a case-control study of predisposing factors. | factors predisposing to clinically significant nosocomial infection with xanthomonas maltophilia were examined in a matched case-control study using multivariate techniques. sixteen cases occurred among cancer patients in a six-month period, including an apparent cluster of three cases in an intensive care unit. these infections were unusually serious; eight patients had disseminated infection caused by x maltophilia and six died as a result of their infections. among the 64 factors that were ex ... | 1990 | 2313082 |
| puncture wound osteochondritis of the foot caused by pseudomonas maltophilia. | 1990 | 2314954 | |
| implications of beta-lactamase-inhibitor combinations. | resistance of many species of bacteria to beta-lactam antibiotics is mediated via inactivation by beta-lactamase. beta-lactamase inhibitors irreversibly bind to beta-lactamases and thus can prevent the destruction of active beta-lactam antibiotics. in the united states three beta-lactam-antibiotic/beta-lactam-inhibitor combinations are commercially available--the orally absorbed amoxicillin/clavulanic acid (a/c), the parenteral formulations of ampicillin/sulbactam (a/s) and ticarcillin/clavulana ... | 1990 | 2319514 |
| selective extraction of outer-membrane proteins from membrane complexes of pseudomonas maltophila by chloroform-methanol. | an organic phase partitioning method is described for the selective purification of outer-membrane proteins (omps) from the total membrane complex of the opportunistic human and sheep pathogen, pseudomonas maltophila. sds-page analysis confirmed that omps purified by chloroform-methanol treatment of the total membrane complex were not only identical to omps extracted from outer-membrane vesicles separated by sucrose gradient density centrifugation, but also possessed little or non-detectable lev ... | 1990 | 2336786 |
| [a method of isolating pseudomonas maltophilia from clinical specimens]. | 1986 | 2434722 | |
| serological classification of xanthomonas maltophilia (pseudomonas maltophilia) based on heat-stable o antigens. | twenty-six serotypes of xanthomonas maltophilia were defined by using 15 antisera described by hugh and ryschenkow (r. hugh and e. ryschenkow, j. gen. microbiol. 26:123-132, 1961) and 11 new antisera. the antisera were prepared by immunizing rabbits with bacterial strains heated at 100 degrees c for 2 h. twelve antisera required adsorptions with cross-reacting heterologous immunizing strains. we tested 275 clinical and environmental strains of x. maltophilia with 26 antisera by the slide aggluti ... | 1989 | 2473089 |
| polychlorinated biphenyl-degrading pseudomonads: survival in mouse intestines and competition with normal flora. | although naturally occurring and mutant organisms, historically, have been released into the environment for various purposes, health concerns associated with the release of microorganisms have recently resurfaced. federal agencies have been given the task of reassuring society that any released organisms are not likely to produce adverse health effects. methods, therefore, for evaluating the potential health effects due to environmental release of mutant and genetically engineered microorganism ... | 1989 | 2492348 |
| immunoelectron microscopic demonstration of an esterase on the outer membrane of xanthomonas maltophilia. | xanthomonas maltophilia (later synonym of pseudomonas maltophilia), an ubiquitous species, is known to show proteolytic and lipolytic activities. a cell-bound esterase which hydrolyzes beta-naphthyl acetate during growth has been extracted from a strain isolated from soil. because of its strongly hydrophobic character, the enzyme could be efficiently solubilized only by triton x-100. this nonionic detergent must be added in polyacrylamide gels to permit migration. polyclonal rabbit antibodies ra ... | 1989 | 2495761 |
| comparative in vitro activity of lomefloxacin, a new difluoroquinolone. | the in vitro activity of lomefloxacin, a new difluoroquinolone, was compared with that of norfloxacin, ciprofloxacin, gentamicin and ceftazidime against a total of 577 recent clinical isolates. mics were determined by a standard agar dilution procedure, and two inocula (10(4) and 10(6) cfu) were used throughout. lomefloxacin inhibited most species of the enterobacteriaceae, staphylococcus aureus (including methicillin-resistant strains) and haemophilus influenzae at less than or equal to 1 mg/l. ... | 1989 | 2498101 |
| isolation and characterization of monoclonal antibodies against alkaline phosphatase of pseudomonas aeruginosa. | monoclonal antibodies against the alkaline phosphatase of pseudomonas aeruginosa were produced from spleen cells of balb/c mice primed with purified alkaline phosphatase of p. aeruginosa atcc 10145 and sp20/ag-14 myeloma cells. the eight stable clones established produced antibodies that reacted by enzyme-linked immunosorbent and indirect immunofluorescence assays with all bacterial strains of p. aeruginosa, including the 17 serotypes and two nontypable strains. three of the clones cross-reacted ... | 1989 | 2501343 |
| species-specific interpretive breakpoints for ciprofloxacin disk diffusion susceptibility testing. | when ciprofloxacin was introduced on the swedish market the recommended interpretive standards for disk diffusion susceptibility testing using a 10 microgram disk were: sensitive greater than or equal to 24 mm (mic less than or equal to 1 mg/l) and resistant less than 18 mm (mic greater than 4 mg/l), except for enterococci where s greater than or equal to 18 mm and r less than 14 mm were recommended. a quality control study revealed that the accuracy of the routine susceptibility testing of cipr ... | 1989 | 2502836 |
| demonstration and partial characterization of adp-ribosylation in pseudomonas maltophilia. | adp-ribosylation of proteins occurs in many eukaryotes, and it is also the mechanism of action of a growing number of important bacterial toxins. to date, however, there is only one well-characterized adp-ribosylation system where the adp-ribosyltransferase and the substrate protein are both bacterial in origin, namely within the nitrogen-fixing bacterium rhodospirillum rubrum. the present paper demonstrates the endogenous adp-ribosylation of two proteins of mr 32,000 and 20,000 within pseudomon ... | 1989 | 2505752 |
| in vitro activity of pd 117596-2, a broad-spectrum difluoroquinolone. | the activity of pd 117596-2, a novel quinolone, was compared to that of other quinolones, ceftazidime, imipenem and gentamicin. pd 117596-2 inhibited most enterobacteriaceae at concentrations less than 0.25 micrograms/ml, being equal or superior in activity to ciprofloxacin and 2- to 4-fold more active than ofloxacin. it inhibited ceftazidime-resistant enterobacter spp., citrobacter spp. and serratia marcescens. the mic90 for pseudomonas aeruginosa, including strains with imipenem mics of 8 micr ... | 1989 | 2506029 |
| [susceptibility of clinical isolates to aztreonam]. | in vitro antibacterial activities of 9 antibiotics including aztreonam (azt) against clinically isolated gram-negative bacteria were determined using mic-2000 plus system. bacteria were isolated from clinical materials in saga medical school during a period from may 1987 to march 1988. summarized results were as follows: 1. azt showed excellent antibacterial activities against escherichia coli, klebsiella pneumoniae, proteus sp. and haemophilus influenzae, and mic80 values of azt against these o ... | 1989 | 2507799 |
| decreased outer membrane permeability in imipenem-resistant mutants of pseudomonas aeruginosa. | the outer membrane of imipenem-resistant mutants of pseudomonas aeruginosa was shown to have decreased permeability to imipenem but not to cephaloridine. these experiments were performed with intact cells and liposomes containing imipenem-hydrolyzing beta-lactamase derived from pseudomonas maltophilia, in both cases utilizing an imipenem concentration of 50 microm. in contrast, liposome swelling assays using imipenem at 8 mm detected no significant difference between the imipenem-resistant mutan ... | 1989 | 2508541 |
| in vitro and in vivo antibacterial activities of bo-1341, a new antipseudomonal cephalosporin. | bo-1341, a new antipseudomonal semisynthetic cephalosporin, was evaluated for in vitro and in vivo antibacterial activities in comparison with ceftazidime, cefotaxime, and cefoperazone. the in vitro activity of bo-1341 was generally superior or comparable to the activities of the reference antibiotics against clinical isolates of the family enterobacteriaceae. bo-1341 was highly active against pseudomonas aeruginosa (mic for 90% of the strains tested, 1.56 micrograms/ml), pseudomonas maltophilia ... | 1989 | 2510590 |
| in vitro antibacterial activity and beta-lactamase stability of the new carbapenem sm-7338. | the in vitro activity of the new carbapenem sm-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. sm-7338 showed good activity against a broad spectrum of gram-positive and gram-negative bacteria. sm-7338 was very active against gram-negative bacteria, inhibiting all enterobacteriaceae, except 25% of serratia marcescens isolates, at a concentration of 0.78 mg/l. sm-7338 inhibited the majority of pseu ... | 1989 | 2512140 |
| [fulminating pseudomonas maltophilia septicemia during treatment with imipenem and amikacin]. | 1989 | 2522211 | |
| a peptidyl dipeptidase-4 from pseudomonas maltophilia: purification and properties. | a peptidyl dipeptidase-4 (bacterial pdp-4) was purified to near homogeneity from a supernatant of pseudomonas maltophilia extracellular medium. bacterial pdp-4 is a single-polypeptide-chain enzyme, 82 kda, with an alkaline isoelectric point. peptides susceptible to hydrolysis by bacterial pdp-4 include angiotensin 1, bradykinin, enkephalins, atriopeptin 2, and smaller synthetic peptides. n-acylated tripeptides are hydrolyzed, but free tripeptides are not. a free carboxy terminus is required for ... | 1989 | 2539048 |
| comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. | the in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. the two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-producing strains of haemophilus influenzae, branhamella catarrhalis, and methicillin-susceptible staphylococcus aureus; all strains were su ... | 1989 | 2552904 |
| amino acid residues essential for catalysis by peptidyl dipeptidase-4 from pseudomonas maltophilia. | to assess residues essential for catalysis by prokaryotic peptidyl dipeptidase-4, the enzyme was subjected to chemical modification by a series of reagents. treatment with either tetranitromethane or n-acetylimidazole abolished catalytic activity. hydroxylamine reversed inactivation by acetylimidazole only. thus, an essential tyrosine is indicated. enzymatic activity also was quenched by either trinitrobenzenesulfonic acid or diethyl pyrocarbonate. inactivation by these reagents was not reversed ... | 1989 | 2563225 |
| detection of essential arginine in bacterial peptidyl dipeptidase-4: arginine is not the anion binding site. | peptidyl dipeptidase-4 from pseudomonas maltophilia was modified with the arginine reagents p-hydroxyphenylglyoxal and 2,3-butanedione. the enzyme was inactivated in a pseudo-first-order manner by p-hydroxyphenylglyoxal with a half-time of 72 min. inactivation by 2,3-butanedione was biphasic with a rapid phase followed by a slower inactivation to less than 10% activity within 24h. the competitive inhibitor thiorphan protected against inactivation by phydroxyphenylglyoxal and by 2,3-butanedione a ... | 1989 | 2653317 |
| in vitro antibacterial activity of sm-7338, a carbapenem antibiotic with stability to dehydropeptidase i. | sm-7338, a new carbapenem antibiotic, was demonstrated to have potent antibacterial activity against a broad spectrum of aerobes, including staphylococcus aureus, beta-hemolytic streptococci, streptococcus pneumoniae, haemophilus influenzae, neisseria spp., members of the family enterobacteriaceae, pseudomonas spp., and gram-positive and gram-negative anaerobes in a collection of 1,102 unselected clinical isolates. at a concentration of 0.5 micrograms/ml, sm-7338 inhibited 90% of these strains. ... | 1989 | 2655530 |
| multicenter in vitro evaluation of sm-7338, a new carbapenem. | a new carbapenem, sm-7338, was compared with imipenem, cefotaxime, and ceftazidime at five medical centers. nearly 6,000 strains were tested by reference methods of the national committee for clinical laboratory standards, and sm-7338 inhibited the largest percentage of gram-negative bacilli. its spectrum included all members of the family enterobacteriaceae (99.7% were susceptible to less than or equal to 4 micrograms/ml), pseudomonas spp. (but not xanthomonas maltophilia), and acinetobacter sp ... | 1989 | 2658796 |
| [clinical experience of chemotherapy with cefmetazole for severe infections accompanying malignant hematological disorders]. | we made an attempt to treat with cefmetazole (cmz) 25 patients who developed severe infectious diseases while suffering with granulocytopenia associated with the treatment of malignant hematological disorders. 1. determination of bacteriological efficacy while 20 strains were isolated and identified from 15 patients, no significant bacteria were detected in 9 patients. isolates obtained were: 5 strains of enterococcus faecalis, 3 strains of haemophilus influenzae, 2 strains of staphylococcus epi ... | 1989 | 2664248 |
| [susceptibilities of clinical isolates to antibacterial agents. a study mainly focused on ofloxacin (the second report). reported by the research group for testing ofloxacin susceptibility on clinical isolates]. | susceptibilities of various clinical isolates to ofloxacin (oflx) and other antibacterial drugs were examined at 128 hospital laboratories in 36 prefectures throughout japan between april, 1986 and march, 1987. the results were totalized with an emphasis mainly on oflx and were compared with data obtained in the previous year. in this study, identification and susceptibility tests of the isolates were carried out at each hospital laboratory and the tests were performed according to the 1-dilutio ... | 1989 | 2664255 |
| [evaluation of a new semi-automatic method of identifying enterobacteriaceae, m.i.s.-enterobacteriaceae]. | m.i.s.-enterobacteriaceae is a new kit for identifying enterobacteriaceae using a microplate consisting of 21 biochemical characters with automated reading and interpretation. the validity of this method was studied by the identification of 350 strains of enterobacteria belonging to 44 species and comparison with the classical method of identification in test-tubes. results showed a diagnosis accuracy of 96 p. cent at the species level and 97.7 p. cent at the genus level. diagnosis accuracy reac ... | 1989 | 2665580 |
| laboratory survey of fluoroquinolone activity. | fluoroquinolones are active against a wide variety of bacteria. the antibacterial spectra of fluoroquinolones encompass staphylococci, bacillus species, and corynebacterium species implicated in infections of the immunocompromised host; enterobacteriaceae; most intestinal pathogens; and many gram-negative organisms commonly causing nosocomial infections. haemophilus influenzae, haemophilus ducreyi, neisseria gonorrhoeae, neisseria meningitidis, and branhamella catarrhalis are highly susceptible ... | 1989 | 2672262 |
| comparative in vitro activity of a new quinolone, am-1091. | the in vitro activity of a new quinolone, am-1091 [7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro- 4-oxo- 3-quinoline carboxylic acid hydrochloride], was compared with those of ciprofloxacin, ofloxacin, beta-lactams, and gentamicin. am-1091 inhibited 90% of the isolates of the family enterobacteriaceae at less than or equal to 0.12 micrograms/ml. for many species am-1091 was 2-fold more active than ciprofloxacin and 2- to 32-fold more active than ofloxacin. it inhibited e ... | 1989 | 2675753 |
| the barrier function of the outer membrane of pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics. | this paper reports that the efficiency of solute diffusion through the outer membrane of pseudomonas maltophilia is roughly 3 to 5% of that of escherichia coli. this is despite the fact that the outer membrane pore(s) is only a little smaller than that of e. coli. these results suggest that p. maltophilia has a low copy number of porin(s). the outer membrane of antibiotic resistant clinical isolates showed even less efficient permeability towards saccharides and antibiotics than the laboratory s ... | 1989 | 2676712 |
| in vitro and in vivo activities of qa-241, a new tricyclic quinolone derivative. | the in vitro susceptibilities of 1,310 clinical isolates to qa-241, a novel tricyclic quinolone, were evaluated in comparison with susceptibilities to norfloxacin, ofloxacin, enoxacin, and ciprofloxacin. the mics of qa-241 for 90% of staphylococci, enterococcus faecalis isolates, and streptococcal species ranged from 1.56 to 6.25 micrograms/ml, and the activity of qa-241 was similar to those of norfloxacin and enoxacin but two to four times less potent than those of ofloxacin and ciprofloxacin. ... | 1989 | 2679369 |
| the carbapenems: new broad spectrum beta-lactam antibiotics. | the carbapenems differ from the penicillins (penams) in having an unsaturated bond between c2 and c3 and a carbon atom replacing sulphur at position 1 of the thiazolidine ring. the various carbapenems differ primarily in the configuration of the side chains at c2 and c6. carbapenems include the thienamycins, olivanic acids, carpetimycins, asparenomycins, pluracidomycins, and other natural and semi-synthetic compounds. carbapenems vary in their stability and resistance to beta-lactamases, ability ... | 1989 | 2681123 |
| therapeutic activity of meropenem in experimental infections. | meropenem and comparative antibiotics were evaluated in five models of infection. all antibiotics were administered parenterally; imipenem was used in combination with cilastatin but meropenem and other agents were given alone. generalized infections in mice caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, serratia marcescens, proteus mirabilis or pseudomonas aeruginosa all responded to low doses of meropenem or imipenem. immunocompromised mice infected with ps. aerug ... | 1989 | 2681126 |
| xanthomonas maltophilia: an emerging nosocomial pathogen. | xanthomonas maltophilia is a potentially pathogenic organism with a broad clinical spectrum. nosocomial colonization and infection are the most common manifestations. the incidence of clinical isolation of x. maltophilia is on the rise, possibly in part because of the selective pressure from the new antimicrobial agents to which it is resistant. the organism is usually resistant to commonly used antimicrobial agents, including most cephalosporins, aztreonam, antipseudomonal penicillins, imipenem ... | 1989 | 2682049 |
| intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. | the efficacy and toxicity of sequential intravenous and oral ciprofloxacin therapy was compared with intravenously administered ceftazidime in a prospective, randomized, controlled, non-blinded trial. thirty-two patients (16 patients receiving ciprofloxacin and 16 patients receiving ceftazidime) with 38 infections caused by susceptible pseudomonas aeruginosa, enteric gram-negative rods, salmonella group b, serratia marcescens, pseudomonas cepacia, and xanthomonas maltophilia at various sites wer ... | 1989 | 2686417 |
| recovery of bacteria from reprocessed high flux dialyzers after bacterial contamination of the header spaces and o-rings. | the centers for disease control (cdc) have received reports of bacteremia in patients on high flux dialysis attributed to contamination of dialyzer header spaces or o-rings. a study was performed in which header spaces and o-rings of hemoflow f-80 dialyzers (fresenius ag, bad homburg, frg) were exposed to an aqueous suspension of xanthomonas maltophilia and mycobacterium chelonae for 1 hour. after exposure, the dialyzers were reprocessed manually with 4% formaldehyde, 4% renalin, 2.5% renalin, o ... | 1989 | 2688713 |
| comparative in vitro antibacterial activity of the new carbapenem meropenem (sm-7338). | the in vitro antimicrobial activity of the new carbapenem meropenem (sm-7338) was determined by an agar dilution method in comparison with imipenem, ticarcillin/calvulanic acid, ceftazidime and the fourth-generation cephalosporin cefepime (bmy 28142). meropenem showed superior activity against enterobacteriaceae (mic90 less than or equal to 0.06 mg/l) and against non-fermentative gram-negative rods, with the exception of xanthomonas maltophilia. meropenem had excellent activity against beta-lact ... | 1989 | 2695328 |
| isolation and characterization of thymidylate synthetase mutants of xanthomonas maltophilia. | thymidylate synthetase mutants of xanthomonas maltophilia atcc 13270 were isolated on a solid minimal medium containing 50 mg/l thymidine and a high concentration of trimethoprim (500 mg/l). it was found that a high concentration of trimethoprim was required to prevent background growth of the wild-type strain. the isolated mutants could grow on thymidine or dtmp at a concentration of 50 mg/l while they were unable to grow on 1000 mg/l thymine or 50 mg/l deoxyuridine. thymidylate synthetase acti ... | 1989 | 2705859 |
| observations on cell-wall deficient forms of pseudomonas maltophilia. | pseudomonas maltophilia cell-wall deficient forms were induced using a medium containing carbenicillin and polyvinyl pyrrolidone. scanning electron microscopy proved to be a very effective method of demonstrating the various phases. it is suggested that the rapid rate of reversion to bacterial forms could have been due to plasmids. | 1989 | 2739580 |
| studies on the microflora associated with xenic cultures of entamoeba gingivalis. | the microflora associated with xenic stock cultures (atcc 30927) of entamoeba gingivalis, the major protozoan of the human oral cavity, were isolated and identified as citrobacter diversus, yersinia enterocolitica, acinetobacter anitratus and pseudomonas maltophilia. in studies to determine whether the bacterial isolates were able to utilize rice starch as a sole carbon source, y. enterocolitica exhibited excellent growth in rice starch minimal medium and tysgm-9 medium (with rice starch), but g ... | 1989 | 2739589 |
| physiological studies of the regulation of beta-lactamase expression in pseudomonas maltophilia. | the kinetics of beta-lactamase induction in pseudomonas maltophilia iid1275/873 were investigated. upon induction with beta-lactam antibiotics, a correlation was seen between the increase in specific beta-lactamase activity and the generation time, as well as the concentration of inducer in the medium. the specific beta-lactamase activity increased slowly within the first 0.5 generation and then more rapidly; it decreased regularly after about 2 generations of growth in the presence of inducer. ... | 1989 | 2783690 |
| resistance of xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. | we examined the susceptibility of 50 isolates of xanthomonas maltophilia and the effect of beta-lactamase inhibitors upon the susceptibility. the majority of isolates were resistant to azlocillin, piperacillin, mezlocillin, ticarcillin, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, and ceftazidime. all isolates were resistant to imipenem, cgp 31608, aztreonam, and carumonam. although disk susceptibility tests showed that the combination of clavulanate with ticarcillin inhibited many isolat ... | 1989 | 2791491 |
| in vitro activity of me1228, a new parenteral cephalosporin. | me1228 is a new cephalosporin with an iminocarboxymethyl moiety on the acyl side chain and a novel pyridiniumthiomethyl group at position 3 of the bicyclic ring. its activity was compared with those of ceftazidime, imipenem, piperacillin, and gentamicin. me1228 inhibited most members of the family enterobacteriaceae, except for some enterobacter spp. and citrobacter freundii, at less than or equal to 0.25 micrograms/ml, and it inhibited gentamicin- and piperacillin-resistant isolates. it had mic ... | 1989 | 2802554 |
| comparative in-vitro activity of meropenem against clinical isolates including enterobacteriaceae with expanded-spectrum beta-lactamases. | meropenem, a new parenteral carbapenem, was tested in vitro by an agar-dilution method against 373 standard strains (aerobes and anaerobes) and against nine expanded-spectrum beta-lactamase-producing strains and their transconjugants (5 ctx-1, 2 caz-1, 2 caz-2). meropenem was compared with methicillin, imipenem, piperacillin, cefoxitin, cefotaxime, ceftazidime, gentamicin, chloramphenicol, clindamycin, ciprofloxacin, vancomycin and metronidazole. meropenem and imipenem exhibited an extended spec ... | 1989 | 2808205 |
| meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. | the activity of meropenem, a new carbapenem, was determined against 82 gram-negative bacteria in agar dilution tests. many of these isolates were resistant to one or more beta-lactam antibiotics and the mechanisms responsible for the resistance had been characterized. the production of beta-lactamases had little influence on susceptibility to either meropenem or imipenem except in tests with aeromonas hydrophila and pseudomonas (xanthomonas) maltophilia. these species produced metalloenzymes cap ... | 1989 | 2808207 |
| comparative in-vitro activity of meropenem on clinical isolates from the united kingdom. | mics of meropenem were determined for a wide range of common bacteria of clinical importance. for enterobacteriaceae, aeromonas spp., haemophilus influenzae, branhamella catarrhalis, neisseria gonorrhoeae, gardnerella vaginalis, campylobacter coli/jejuni, beta-haemolytic streptococci and anaerobes other than clostridium difficile, mics were almost always within the range 0.002-0.5 mg/l. the activity of meropenem for these organisms was always greater than that of imipenem and piperacillin, and w ... | 1989 | 2808214 |
| in-vitro activity of meropenem against clinical isolates obtained in canada. | the in-vitro activity of meropenem, a new parenteral carbapenem, was compared with that of imipenem, ceftazidime, cefotaxime, piperacillin, gentamicin and, where appropriate, other antibiotics against recent clinical isolates and characterized beta-lactamase producers. mics were determined by a standard agar dilution procedure and two inocula (10(4) and 10(6) cfu) were used throughout. meropenem inhibited 90% of isolates of escherichia coli, klebsiella pneumoniae, proteus mirabilis, indole-posit ... | 1989 | 2808216 |
| bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including mycobacterium avium complex. | for clinical isolates the mics of meropenem were significantly lower than the mics of imipenem, especially against pseudomonas aeruginosa. furthermore, meropenem was bactericidal for pseudomonas spp., including ps. (xanthomonas) maltophilia, and staphylococci, with mbcs on average only two-fold above the respective mics. the bactericidal activity was confirmed by killing curve assays. strains with high meropenem mics (greater than or equal to 8 mg/l) were killed by a combination of the carbapene ... | 1989 | 2808217 |
| molecular cloning and expression of the imipenem-hydrolyzing beta-lactamase gene from pseudomonas maltophilia in escherichia coli. | the l-1 penicillinase structural gene, blas, from pseudomonas maltophilia was cloned into the vector pacyc184. the pmon01 recombinant plasmid selected by ampicillin resistance carried a 2.6-kilobase (kb) sau3a fragment of p. maltophilia dna and was confirmed to express l-1 beta-lactamase by comparative isoelectric focusing. a detailed physical map was constructed, and the blas structural gene was localized with a 17-mer oligonucleotide mixed probe encoding the l-1 nh2-terminal amino acid sequenc ... | 1988 | 2847278 |
| selective medium for isolation of xanthomonas maltophilia from soil and rhizosphere environments. | a selective medium (xmsm) was developed for isolation of xanthomonas maltophilia from bulk soil and plant rhizosphere environments. the xmsm basal medium contained maltose, tryptone, bromthymol blue, and agar. antibiotics added to select for x. maltophilia were cycloheximide, nystatin, cephalexin, bacitracin, penicillin g, novobiocin, neomycin sulfate, and tobramycin. a comparison was made between xmsm and 1/10-strength tryptic soy broth agar for recovery of x. maltophilia from sterile and nonst ... | 1989 | 2930173 |
| in vitro evaluation of a-56619 and a-56620, two new quinolones. | the in vitro activities of two new aryl-fluoroquinolones (a-56619 and a-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. all six quinolones had broad spectra of antibacterial activity; the streptococci, pseudomonas maltophilia, and pseudomonas cepacia were the least susceptible. a-56619, a-56620, and chloramphenicol had similar activity against anaerobic bacteria. with both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. by reg ... | 1986 | 2942099 |
| identification and characterisation of pmaci an endonuclease of novel specificity from pseudomonas maltophila. | we report the use of monoq fplc (fast protein liquid chromatography) for the rapid purification of a novel type ii restriction endonuclease pmaci, from pseudomonas maltophila, which recognises the sequence 5'-cac decreases gtg-3'. the resulting enzyme is free of other nucleases to a level suitable for its characterisation by multiple-substrate digestion and dna sequencing techniques. this method appears to be widely applicable and we have used it for the isolation of restriction endonucleases of ... | 1986 | 3005970 |
| ketopantoic acid reductase of pseudomonas maltophilia 845. purification, characterization, and role in pantothenate biosynthesis. | ketopantoic acid reductase (ec 1.1.1.169), an enzyme that catalyzes the formation of d-(-)-pantoic acid from ketopantoic acid, was purified 6,000-fold to apparent homogeneity with a 35% overall recovery from pseudomonas maltophilia 845 and then crystallized. the relative molecular mass of the native enzyme, as estimated by the sedimentation equilibrium method, is 87,000 +/- 5,000, and the subunit molecular mass is 30,500. the enzyme shows high specificity for ketopantoic acid as a substrate (km ... | 1988 | 3042788 |
| cloning and expression of the imipenem-hydrolyzing beta-lactamase operon from pseudomonas maltophilia in escherichia coli. | the l-1 penicillinase structural gene, blas, from pseudomonas maltophilia has been cloned into the vector pacyc184. the pmon01 recombinant plasmid selected by ampicillin resistance carried a 2.6-kilobase sau3a fragment of p. maltophilia dna and was confirmed to express l-1 beta-lactamase by comparative isoelectric focusing. a detailed physical map was constructed, and the blas structural gene was localized with a 17-mer oligonucleotide mixed probe encoding the l-1 n-terminal amino acid sequence. ... | 1988 | 3046482 |
| [bacterial infection agents in hospitalized patients]. | during six months the pattern of microbial isolates has been analysed from 1492 urinary tract infections, from 1445 wound infections, from 451 bronchial secretions, from 3067 blood cultures, from 116 peritoneal swabs and from 39 cerebrospinal fluids. all the specimens investigated were taken from patients of surgical, neurosurgical, internal wards and two intensive care units. in total, the most frequent isolates were grampositive microorganisms like staphylococus aureus, straphylococcus epiderm ... | 1986 | 3107262 |
| comparative disk and broth dilution susceptibility test results with ticarcillin and timentin against pseudomonas aeruginosa and pseudomonas maltophilia. | a total of 500 clinical isolates of pseudomonas aeruginosa and 14 isolates of pseudomonas maltophilia were examined for susceptibility to ticarcillin and timentin (ticarcillin plus clavulanic acid). clavulanic acid enhanced the activity of ticarcillin against only 34 of 500 isolates of p. aeruginosa. among 23 isolates of p. aeruginosa, that had yielded divergent disk diffusion results, there were 3 major discrepancies (3 = ticarcillin-resistant by disk diffusion, but susceptible by broth dilutio ... | 1987 | 3117502 |
| qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. | a microbiological analysis of 102 patients suffering from cystic fibrosis was conducted over a 22 month period. 20 microbial species with the following incidence were identified: pseudomonas aeruginosa: 83.4%; candida albicans: 29.4%; staphylococcus aureus: 24.5%; staphylococcus epidermidis: 11.8%; haemophilus influenzae: 11.8%; streptococcus pneumoniae; 6.9%; pseudomonas maltophilia: 6.8%; aspergillus fumigatus: 5.9%. other species were present in less than 5% of the patients. in the majority o ... | 1987 | 3117700 |
| [automated micromethod for the determination of the utilization of carbon sources by clinically significant pseudomonas species]. | the assimilation of 43 different carbon substrates by 93 clinical strains of pseudomonas aeruginosa was studied by a new miniaturized rapid method. reading of assimilation results was done photometrically after 18-20 h incubation and the resulting data were captured and stored by a microcomputer. the differentiating capacity of the assimilation tests were verified by comparing the results of 41 strains of pseudomonas fluorescens, 48 strains of pseudomonas putida, 52 strains of pseudomonas maltop ... | 1987 | 3118596 |
| in vitro activity of e-1040, a novel cephalosporin with potent activity against pseudomonas aeruginosa. | the in vitro activity of e-1040 [(6r,7r)-3-[(4-carbamoyl-1-quinuclidinio)methyl]-7-[2-(5-amino-1,2 ,4- thiadiazol-3-yl)-(z)-2-methoxyiminoacetoamido]-8-oxo-5-thia- 1- azabicyclo(4,2,0)oct-2-ene-2-carboxylate], a novel cephalosporin, was compared with that of ceftazidime, cefpirome, cefepime, imipenem, and gentamicin. e-1040 inhibited 50% of members of the family enterobacteriaceae, pseudomonas aeruginosa, and haemophilus and neisseria species at less than or equal to 0.25 microgram/ml, and the m ... | 1988 | 3150915 |
| ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. | evaluations of 5-microgram ciprofloxacin disk diffusion susceptibility tests were performed independently by seven different investigators. the results of the separate tests were combined to increase the number of resistant strains in the challenge set of microorganisms. based on data with 2,652 isolates, the following interpretive breakpoints are tentatively proposed for use in ongoing clinical trials of ciprofloxacin: less than or equal to 15 mm, resistant (mic greater than 2.0 micrograms/ml); ... | 1985 | 3159749 |